United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Sanofi to acquire Vigil Neuroscience for $470m to advance TREM2-targeting Alzheimer’s therapy Sanofi to acquire Vigil Neuroscience for $470M, aiming to add VG-3927, a TREM2-based Alzheimer’s drug, to its neurology pipeline. byPallavi MadhirajuMay 23, 2025